Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.

Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.

CRISPR and partner Vertex Pharmaceuticals have applied for authorization of exa-cel, a candidate to treat blood disorders. If all goes well, Wall Street's average forecast for a 70% jump in CRISPR shares within the coming 12 months could happen. CRISPR and Vertex use this technology in exa-cel to tackle the blood disorders beta thalassemia and sickle cell disease.